TAG:
genetic tests
October 8, 2012 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIX No. – October 8, 2012 Issue
Definiens AG, one of the major players in the fast-growing market for digital pathology, raised $12.8 million in additional capital funding. The company, based in Munich, Germany, manufacturers systems for digital image analysis. Definiens stated that the new funds will be used for â…
Pathologists Can Offer ‘Companion Informatics’
By Joseph Burns | From the Volume XIX No. 9 – June 25, 2012 Issue
CEO SUMMARY: Community hospitals are recognizing increased interest in personalized medicine among consumers. One expert predicts that this will create opportunities for hospital labs and pathology groups to add value by offering subspecialty expertise in molecular diagnostics, genetic te…
Exome Sequencing Next “Big Thing†for Diagnosis
By Joseph Burns | From the Volume XIX No. 5 – April 2, 2012 Issue
CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—…
2011’s Top 10 Lab Stories Point to a Busy 2012
By Robert Michel | From the Volume XIX No. 1 – January 9, 2012 Issue
CEO SUMMARY: Given the specific news stories that make up THE DARK REPORT’S list of the “Top Ten Lab Stories for 2011,†it might be said that 2011 was a rather quiet year overshadowed by anticipation of the coming reforms mandated by the Accountable Care Act of 2010. For the clinica…
Why Capitate Genetic and Molecular Test Prices?
By R. Lewis Dark | From the Volume XVIII No. 17 – December 19, 2011 Issue
HOW MANY OF YOU LIVED THROUGH THE DECADE OF THE 1990s and experienced the free fall in the prices managed care plans paid for clinical laboratory testing? In California—at the peak of this insanity—some lab companies offered full risk, capitated contracts for as low as 20¢ PMPM (per member per m…
LabCorp’s BeaconLBS Aims To Manage Genetic Tests
By Joseph Burns | From the Volume XVIII No. 17 – December 19, 2011 Issue
CEO SUMMARY: BeaconLBS is a new business created by Laboratory Corporation of America. It says it wants to help health insurance plans manage molecular diagnostics and genetic testing. BeaconLBS is now recruiting other clinical labs to join its network and is meeting with payers to offer …
December 19, 2011 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVIII No. 17 – December 19, 2011 Issue
Expanded genetic testing for cancer patients in the United Kingdom is one goal of a new effort by the Stratified Medicine Programme at Cancer Research UK. Officials want to ensure that the right genetic tests are available to support use of new therapeutic drugs for …
Molecular Code Stacks Now in the Payers’ Bull’s Eye
By R. Lewis Dark | From the Volume XVIII No. 16 – November 28, 2011 Issue
LIKE A STEAM BOILER READY TO EXPLODE FROM TOO MUCH PRESSURE, the nation’s health insurers have reached a point of no return on the subject of code-stacked claims for genetic testing and molecular diagnostics assays. Simply put, payers are ready to tackle this sensitive issue. Payers have reasonabl…
Palmetto Execs Explain Molecular Test Policies
By Joseph Burns | From the Volume XVIII No. 16 – November 28, 2011 Issue
CEO SUMMARY: To create more transparency in the process clinical labs use to submit claims for genetic tests, molecular diagnostic tests, and for laboratory-developed tests (LDT), the nation’s largest Medicare Administrative Contractor (MAC) has proposed two new local coverage determina…
Medicare Carrier Plans to Reject Molecular Claims
By Robert Michel | From the Volume XVIII No. 15 – November 7, 2011 Issue
CEO SUMMARY: In September, Palmetto, a Medicare carrier serving California and seven other states, made public two draft local coverage determinations (LCDs) that revamp its coverage guidelines for molecular diagnostic tests (MDT) and laboratory-developed tests (LDT). All labs su…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized